THERADIAG Announces the Launch of 4 New i-Tracker® Kits and the Validation of a New Parameter in the United States
December 02 2021 - 11:45AM
Business Wire
Regulatory News:
THERADIAG (ISIN: FR0004197747, Ticker: ALTER) (Paris:ALTER), a
company specializing in in vitro diagnostics and Theranostics,
today announces the launch of four additional kits in its
i-Tracker® tests range and the validation of a new parameter in the
United States, all dedicated to biotherapy monitoring.
In addition to its eight kits that have already received CE
marking1, Theradiag is expanding its range with 4 more kits of
i-Tracker® tests: i-Tracker® Golimumab, i-Tracker® Anti-Golimumab,
i-Tracker® Rituximab and i-Tracker® Anti-Rituximab, all of which
being adapted to its latest generation random-access analyzer
i-Track10® and the IDS-iSYS automated system manufactured by the
company IDS.
As of the date of this press release, the Golimumab and
anti-Golimumab kits are already CE marked, while the Rituximab and
anti-Rituximab kits will be in the coming weeks. The Golimumab kits
are devoted to monitoring biotherapies used within the framework of
chronic inflammatory diseases treatment in gastroenterology,
rheumatology and dermatology; the Rituximab kits are notably
dedicated to biotherapies used in rheumatology and oncology.
While expanding its range, Theradiag is also strengthening its
offer in the United States. A new parameter has been validated in
the laboratory of Veracyte2, a Theradiag’s partner in the United
States: the Infliximab biosimilar Avsola®. This biosimilar has been
approved by the FDA (Federal Drug Administration) to treat chronic
inflammatory diseases such as rheumatoid arthritis, Crohn disease
and ulcerative colitis. After Inflectra® and Renflexis®, Avsola® is
the third biosimilar validated on Theradiag's OptimAbs Infliximab
test.
Bertrand de Castelnau, CEO of Theradiag, commented: “We
are very proud to announce these two decisive bits of news that
materialize the strategy we have adopted in recent semesters: the
extension of our R&D and the intensification of the
internationalization of our offer. This commercial strategy allows
us to contribute to the development of individualized therapeutic
monitoring of even more biotherapies and for even more patients
around the world”.
About Theradiag
Theradiag is the market leader in biotherapy monitoring.
Capitalizing on its expertise in the diagnostics market, the
Company has been developing, manufacturing, and marketing
innovative in vitro diagnostic (IVD) tests for over 30 years.
Theradiag pioneered “theranostics” testing (combining therapy
with diagnosis), which measures the efficacy of biotherapy in the
treatment of chronic inflammatory diseases. Going beyond mere
diagnosis, Theranostics aims to help clinicians set up “customized
treatment” for each patient. This method favors the
individualization of treatment, evaluation of its efficacy and the
prevention of drug resistance. In response to this challenge,
Theradiag develops and markets the CE-marked TRACKER® range, a
comprehensive solution of inestimable medical value.
The Company is based in Marne-la-Vallée, near Paris, has
operations in over 70 countries and employs over 60 people. In
2020, the Company posted revenue of €10.4 million. The Theradiag
share is listed on Euronext Growth Paris (ISIN: FR0004197747) and
is eligible for the French PEA-PME personal equity plan.
For more information about Theradiag, please visit our website:
https://www.theradiag.com/
1 An initial four kits were granted CE marking in March 2020and
an additional four in January 2021
2 Formerly HalioDx, renamed Veracyte since the acquisition of
the group by the eponymous American company
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211202005645/en/
Theradiag Bertrand de Castelnau CEO/Managing
Director Tel.: +33 (0)1 64 62 10 12
contact@theradiag.com
NewCap Financial Communications &
Investor Relations Pierre Laurent Quentin Massé Tel.:
+33 (0)1 44 71 94 94 theradiag@newcap.eu
NewCap Media Relations Nicolas Mérigeau Tel.: +33
(0)1 44 71 94 98 nmerigeau@newcap.fr
Theradiag (EU:ALTER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Theradiag (EU:ALTER)
Historical Stock Chart
From Apr 2023 to Apr 2024